Autophagy as a therapeutic target for intracranial aneurysm
AssigneeBoard of Regents, The University of Texas System
InventorsDong H. Kim, Yanning Rui, Zhen Xu, John Hagan
Life of this patent
Estimating the term…
Abstract
Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.
Claims16
A method for treating a human subject at risk of suffering from an intracranial aneurysm comprising administering to said human subject a therapeutically effective dose of an autophagy inhibitor, wherein the autophagy inhibitor is selected from the group consisting of wortmannin, chloroquine, clomipramine, 3-Methyladenine, Bafilomycin A1, Pepstatin A, and Pepstatin E-64-d, wherein the human subject carries a variant affecting the expression of a Thrombospondin Type 1 Domain Containing 1 (THSD1) gene.
Dependencies are inferred from the claim text.